Amgen (AMGN) Cash from Financing Activities (2009 - 2026)

Amgen's Cash from Financing Activities history runs 18 years deep, the most recent figure standing at $1.4 billion for Q1 2026.

• In Q1 2026, Cash from Financing Activities rose 134.96% year-over-year to $1.4 billion; the TTM figure through Mar 2026 stood at -$5.3 billion (up 55.0% YoY), while the FY2025 annual figure was -$10.9 billion, down 15.34% from the prior year.
• Cash from Financing Activities was $1.4 billion for Q1 2026 at Amgen, up from -$1.2 billion in the prior quarter.
• In the past five years, Cash from Financing Activities ranged from a high of $21.5 billion in Q1 2023 to a low of -$4.1 billion in Q1 2025.
• Historically, Cash from Financing Activities has averaged -$107.5 million across 5 years, with a median of -$1.4 billion in 2024.
• Biggest YoY gain for Cash from Financing Activities was 712.09% in 2023; the steepest drop was 226.26% in 2023.
• A 5-year view of Cash from Financing Activities shows it stood at -$1.0 billion in 2022, then jumped by 362.54% to $2.8 billion in 2023, then tumbled by 151.09% to -$1.4 billion in 2024, then grew by 12.86% to -$1.2 billion in 2025, then surged by 217.13% to $1.4 billion in 2026.
• The last three Cash from Financing Activities figures came in at $1.4 billion (Q1 2026), -$1.2 billion (Q4 2025), and -$2.9 billion (Q3 2025), per Business Quant data.